WATCH TV LIVE

Tags: Pfizer | ReViral

Pfizer to Buy RSV Drug Developer ReViral for up to $525M

(AP)

Thursday, 07 April 2022 06:58 AM EDT

Pfizer Inc. said Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus.

Click Here to comment on this article

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

Yes, Send Me News Alerts via email

(Optional for Local News)

Privacy: We never share your email address.

Join the Newsmax Community

Read and Post Comments
Please review Community Guidelines before posting a comment.

TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.